A. Drozdowskyj

发表

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

E. Felip, F. de Marinis, G. Altavilla, 2012, The Lancet. Oncology.

Assessment of the Feasibility and Safety of Durvalumab for Treatment of Solid Tumors in Patients With HIV-1 Infection: The Phase 2 DURVAST Study.

B. Clotet, J. Martinez-Picado, J. Prado, 2020, JAMA oncology.

Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients

R. Rosell, A. Giménez-Capitán, N. Karachaliou, 2018, Therapeutic advances in medical oncology.

Integrin-linked kinase (ILK) and src homology 2 domain-containing phosphatase 2 (SHP2): Novel targets in EGFR-mutation positive non-small cell lung cancer (NSCLC)

R. Rosell, A. Cardona, M. Santarpia, 2018, EBioMedicine.

Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.

E. Felip, F. de Marinis, L. Paz-Ares, 2015, JAMA oncology.

EGFR compound mutants and survival on erlotinib in non-small cell lung cancer (NSCLC) patients (p) in the EURTAC study.

E. Felip, R. Rosell, M. Taron, 2012 .

The EPICAL trial, a phase Ib study combining first line afatinib with anti-EGF vaccination in EGFR-mutant metastatic NSCLC.

R. Rosell, E. D'hondt, D. Rodríguez-Abreu, 2021, Lung cancer.

Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts

Michael F. Sharpnack, D. Schadendorf, R. Sullivan, 2018, Journal of Translational Medicine.

Association of PALB2 Messenger RNA Expression with Platinum‐Docetaxel Efficacy in Advanced Non–Small Cell Lung Cancer

R. Rosell, J. Ramírez, B. Massuti, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Multiplex Analysis of CircRNAs from Plasma Extracellular Vesicle-Enriched Samples for the Detection of Early-Stage Non-Small Cell Lung Cancer

R. Rosell, M. Hackenberg, S. Giannoukakos, 2022, Pharmaceutics.

Cancer Stem Cell Biomarkers in EGFR-Mutation-Positive Non-Small-Cell Lung Cancer.

R. Rosell, A. Cardona, A. Giménez-Capitán, 2019, Clinical lung cancer.

Interferon-gamma (INFG), an important marker of response to immune checkpoint blockade (ICB) in non-small cell lung cancer (NSCLC) and melanoma patients.

R. Rosell, N. Karachaliou, D. Rodríguez-Abreu, 2017 .

COVID-19 in melanoma patients: Results of the Spanish Melanoma Group Registry, GRAVID study

S. Puig, R. Rosell, M. Provencio, 2021, Journal of the American Academy of Dermatology.

Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-Small Cell Lung Cancer Associated With Poor Prognosis

M. Okada, T. Mok, S. Ou, 2018, EBioMedicine.

ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer patients with the EGFR T790M mutation.

F. de Marinis, R. Rosell, B. Massuti, 2014, Translational lung cancer research.

Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer

H. Ditzel, E. Felip, M. Larsen, 2017, Nature Communications.

The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR-Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial

E. Felip, R. Rosell, Jia Wei, 2014, Clinical Cancer Research.

Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC

H. Ditzel, F. de Marinis, R. Rosell, 2017, Journal of the National Cancer Institute.

BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer

E. Felip, F. de Marinis, J. Bosch-Barrera, 2015, Scientific Reports.

BRAF Mutations Classes I, II, and III in NSCLC Patients Included in the SLLIP Trial: The Need for a New Pre-Clinical Treatment Rationale

R. Rosell, T. Bivona, J. Berenguer, 2019, Cancers.

Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer

T. Wurdinger, E. Smit, E. Thunnissen, 2015, Oncotarget.

Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer

E. Smit, E. Thunnissen, R. Rosell, 2015, Oncotarget.

BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors

R. Rosell, Álvaro González, J. Cortés, 2015, Melanoma research.

Tracking plasma KRAS mutations (mu) in lung adenocarcinoma (LUAC) patients (p) and branching evolution.

E. Felip, R. Rosell, N. Karachaliou, 2019, Journal of Clinical Oncology.

SARS-CoV-2 infection in patients with melanoma: results of the Spanish Melanoma Group registry

S. Puig, M. Provencio, J. Gardeazabal, 2022, Clinical and Translational Oncology.

Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy

R. Rosell, C. Montagut, V. Soriano, 2018, Melanoma research.

Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL).

J. Bosch-Barrera, R. Rosell, N. Reguart, 2020, Lung cancer.

EML4-ALK rearrangement in blood platelets and outcome to crizotinib in non-small-cell lung cancer patients.

T. Wurdinger, E. Smit, E. Thunnissen, 2015 .

1273POVERALL SURVIVAL ANALYSES OF FIRST-LINE ERLOTINIB VERSUS CHEMOTHERAPY IN THE EURTAC STUDY POPULATION CONTROLLING FOR THE USE OF POST-STUDY THERAPY.

S. Liu, A. Drozdowskyj, R. Rosell, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

BRCA1 Expression and Outcome in Patients With EGFR-Mutant NSCLC Treated With Gefitinib Alone or in Combination With Olaparib

R. Rosell, N. Reguart, R. García-Campelo, 2020, JTO clinical and research reports.

Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts

Michael F. Sharpnack, D. Schadendorf, R. Sullivan, 2018, Journal of Translational Medicine.

Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer

E. Felip, F. de Marinis, J. Bosch-Barrera, 2023, Scientific Reports.

Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies.

A Vergnenegre, X. Chen, X. Qian, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Cancer immunotherapy does not increase the risk of death by COVID-19 in melanoma patients

S. Puig, R. Rosell, M. Provencio, 2020, medRxiv.

Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial

A. Arance, E. Espinosa, C. Montagut, 2021, Nature Communications.

Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A randomized phase 2 study (GOAL, Spanish Lung Cancer Group).

J. Bosch-Barrera, R. Rosell, N. Reguart, 2018 .

OA10.03 YAP-NOTCH and STAT3 Signaling Rebound as a Compensatory Response to Gefitinib or Osimertinib Treatment in EGFR Mutant Lung Cancer

R. Rosell, A. Cardona, P. Ma, 2017 .

E. Felip, F. de Marinis, G. Altavilla, 2012, The Lancet. Oncology.

The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR-Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial

E. Felip, R. Rosell, Jia Wei, 2014, Clinical Cancer Research.

Integrin-linked kinase (ILK) and src homology 2 domain-containing phosphatase 2 (SHP2): Novel targets in EGFR-mutation positive non-small cell lung cancer (NSCLC)

R. Rosell, A. Cardona, M. Santarpia, 2018, EBioMedicine.

Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trial.

F. de Marinis, R. Rosell, A. Vergnenègre, 2015, Future oncology.